en · de · es · fr · pt
sr9009-notes.peptides4800.com › Data › Mechanism And Preclinical Findings — Reference Sheet

Mechanism And Preclinical Findings — Reference Sheet

By Editorial Desk · published 2026-07-23 · last reviewed 2026-08-01 · Data

circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Related pages on this site

Reference notes

History of flow chemistry – history of chemical reactions run in a continuously flowing stream rather than in batch production. History of geochemistry – history of the study of the mechanisms behind major geological systems using chemistry History of aqueous geochemistry – history of the study of the role of various elements in watersheds, including copper, sulfur, mercury, and how elemental fluxes are exchanged through atmospheric-terrestrial-aquatic interactions History of isotope geochemistry – history of the study of the relative and absolute concentrations of the elements and their isotopes using chemistry and geology History of ocean chemistry – history of the study the chemistry of marine environments, including the influences of different variables. History of organic geochemistry – history of the study of the impacts and processes that organisms have had on Earth History of regional, environmental and exploration geochemistry – history of the study of the spatial variation in the chemical composition of materials at the surface of the Earth History of inorganic chemistry – history of the branch of chemistry concerned with the properties and behavior of inorganic compounds. History of nuclear chemistry – history of the subfield of chemistry dealing with radioactivity, nuclear processes and nuclear properties.

20 April – BBC News reports that the SNP will form a minority government if the Scottish Greens vote to end their power-sharing agreement. 21 April – A 20-year-old man is charged after a car appeared to drive at pro-independence marchers in Glasgow the previous day. 22 April – Donna Marie Brand, one of three people convicted of the 1996 murder of Caroline Glachan, is sentenced to life imprisonment with a minimum of 17 years. John-Paul McLaughlan is sentenced to life imprisonment with a minimum of 17 years after admitting the murder of his partner, Stacey Warnock, who was stabbed multiple times following an argument at the couple's home in December 2022. NHS Dumfries and Galloway apologises for any anxiety caused by a cyberattack, described as a "targeted and continued incursion", which occurred in March. 23 April – Two people are taken to hospital after a light aircraft crashes at Monkton near Prestwick Airport. 2024 Scottish government crisis: Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. 25 April – 2024 Scottish government crisis: The Scottish National Party's coalition in the Scottish government with the Scottish Greens collapses as the SNP withdraws. The SNP announce their intention to continue as a minority government. The Scottish Conservatives call a no confidence vote in First Minister Humza Yousaf. 26 April – 2024 Scottish government crisis: Humza Yousaf says he will not resign as first minister of Scotland despite facing a motion of no confidence in his government.

Nandrolone was probably among the first anabolic steroids to be used as a doping agent in sports in the 1960s. It has been banned at the Olympics since 1974. There are many known cases of doping in sports with nandrolone esters by professional athletes.

Sources: en.wikipedia.org

Reference notes

In 2000, the NHTSA released a regulation making trunk releases mandatory for new cars by September of the following year due, in part, to the lobbying efforts of Janette Fennell. In 2003, the IIHS began conducting side impact crash tests. In 2004, NHTSA released new tests designed to test the rollover risk of new cars and SUVs. Only the Mazda RX-8 got a 5-star rating. Also in 2003, the National Highway Traffic Safety Administration (NHTSA) introduced a female counterpart crash test dummy of Hybrid III. This dummy was just a scaled-down version of the original Hybrid III, only representing the smallest 5% of women based on mid-1970s standards. In 2009, Citroën became the first manufacturer to feature "Snowmotion", an Intelligent Anti Skid system developed in conjunction with Bosch, which gives drivers a level of control in extreme ice or snow conditions similar to a 4x4. In 2009, NHTSA upgraded its roof-crush standard for vehicles weighing 6000 pounds or less. The new standard increased the crush load requirement from 1.5 to 3 times the vehicle's curb weight.

Knowledge base annotation is done based on the information of gene attribute, protein function and its metabolism. In this type of annotation more emphasis is given to genetic variation that disrupts the protein function domain, protein-protein interaction and biological pathway. The non-coding region of genome contain many important regulatory elements including promoter, enhancer and insulator, any kind of change in this regulatory region can change the functionality of that protein. The mutation in DNA can change the RNA sequence and then influence the RNA secondary structure, RNA binding protein recognition and miRNA binding activity. This method mainly identifies variant function based on the information whether the variant loci are in the known functional region that harbor genomic or epigenomic signals. The function of non-coding variants are extensive in terms of the affected genomic region and they involve in almost all processes of gene regulation from transcriptional to post translational level

Gastrointestinal side-effects (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem. It is also a cause of drug-induced hepatitis. Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis. Thyroid goitre is also a side-effect because aminosalicylic acid inhibits the synthesis of thyroid hormones. Drug interactions include elevated phenytoin levels. When taken with rifampicin, the levels of rifampicin in the blood fall by about half. It is not known whether it will harm an unborn baby. With heat, 4-aminosalicylic acid is decarboxylated to produce CO2 and 3-aminophenol.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network